Contributors:
Ajay Karandikar, Founder & CEO, Omnitheia
Renata Crome, Advisory Board, Omnitheia (Former Deputy Global Head, Roche)

Reading Time: 6 minutes

The Clinical Attrition Reality

The pharmaceutical industry is currently defined by a significant paradox. While the average cost to develop a single drug has soared to $2.3 billion, the probability of success remains alarmingly low. Nine out of ten drugs fail to navigate the path through clinical development and regulatory approval.

This high rate of clinical failure is the primary reason drugs never reach patients and why promising assets lose valuation. This briefing explores how these outcomes can be improved by replacing fragmented data with a triangulated validation of potential.

1. Bridging the Credibility Gap

Establishing the Clinical and Commercial Value Proposition for Innovative Biotechs and Research Charities

Innovative biotechs and non-profit life science clusters often encounter a persistent institutional bias when engaging with global pharmaceutical companies. In an environment where 90% of assets fail, these large-scale players frequently perceive smaller or non-traditional entities as carrying a higher operational risk.

The Strategy of Evidence-Based Validation

To secure high-value partnerships, biotechs must move beyond early-stage R&D findings. Drawing on the experience of major global research charities and independent institutes, we see that the most effective way to overcome preconceived notions is to present a clinical and commercial value proposition that performs at a global standard.

When these organizations present a defensible validation of their asset, they transition from discovery-phase entities to essential strategic partners capable of solving complex R&D challenges for the world’s largest pharmaceutical companies.

2. Consolidating Business Intelligence

Addressing the Cost of Fragmented Data Sources

The current industry standard for Business Intelligence has historically been inefficient. Strategic teams are often forced to navigate a complex “menu” of multiple high-cost secondary data subscriptions, each utilizing varying methodologies and offering siloed insights.

This reliance on fragmented, point-in-time data is a major driver of strategic misalignment and clinical failure.

The Solution: A Unified Data Ecosystem

Omnitheia addresses this systemic inefficiency by providing a single, unified platform that consolidates over 100,000 curated secondary data sources.

By replacing siloed subscriptions with a continuous stream of validated intelligence, innovative biotechs can identify insights that traditional Market Research frequently overlooks. This ensures that a development strategy is based on a comprehensive, real-time view of the scientific and commercial landscape, rather than disconnected data points from multiple providers.

3. The Triangulated Validation of Potential

To navigate the 10% Probability of Success (PoS) reality, a biotech must integrate its internal findings with external market and expert insights.

Integrating these three distinct evidence streams enables a robust validation of clinical & commercial potential:

• Internal Clinical Data: Analysis of the asset’s unique biological, safety, and efficacy data.
• Published Intelligence: Utilizing a landscape of over 100,000 validated secondary sources to serve as a data benchmark for the asset’s performance.
• Primary Market Research (PMR): Direct insights from the clinical environment (KOLs, Payers, HCPs) to provide real-world validation of clinical and commercial claims.

The Omnitheia Advantage

While integrating these streams is essential for surviving due diligence, the manual process is often slow and prone to error.

Omnitheia provides the technology to make this integration seamless, allowing biotechs to create a validated view of potential that secures the funding and licensing interest necessary for late-stage development and regulatory approval.

4. Unlocking the Value of AI through Data Accuracy and Verification

AI curated specifically for the life sciences enables the analysis of massive datasets embedded within hundreds of thousands of scientific publications.

Historically, accessing and synthesizing these insights required a level of time and resource investment that was often prohibitive for even the most well-funded teams. While this technology provides immense potential, the benefits can only be realized if both the inputs and the outputs are strictly controlled.

The Requirement for Absolute Accuracy

In the life science industry, failing to achieve this level of control is dangerous. Inaccurate data can lead to failed trials, unsuccessful licensing deals, and regulatory approval failures.

Most importantly, errors in data can ultimately deny or delay patient access to life-saving treatments. For Clinical, Commercial, Licensing, and Medical Affairs leaders, accuracy is a requirement for survival.

The Control Centre Approach

At Omnitheia, we utilize a control centre that curates, validates, and monitors accurate, credible sources. Our proprietary technology also controls the quality of every output to eliminate data noise and hallucinations.

By providing a Confidence Score for every insight, we enable the industry to harness the speed of AI to identify new opportunities while providing evidence-based verification of the accuracy of the results.

The Path to a Licensing Win: Three Essentials for Competitive Differentiation

If a Phase 2 or Phase 3 biotech company approaches a Global Top 10 pharma company to secure a licensing deal, what three things must they bring to the table?

To differentiate their asset’s potential vs competitors and to move a deal forward, a biotech must satisfy these requirements:

1. Validating the High-Value Problem

The key is to present and validate the specific, high-value problem the drug asset solves.

This requires a rigorous assessment of the clinical and commercial unmet need. You must prove the drug solves a specific, significant challenge that justifies a partner’s investment and provides a clear market advantage.

2. Know Your Biology (Biological Validation)

Strategic partners require deep confidence in the Mechanism of Action (MoA) and the identification of validated biomarkers.

You must provide comprehensive data on safety and efficacy, demonstrating a superior profile when compared to the current Standard of Care (SoC). This biological certainty is what de-risks the asset during the due diligence process.

3. The Integrated Value Story

A winning strategy connects the laboratory to the real world.

This requires synthesizing expert insights and Real-World Evidence (RWE) from a broad spectrum of stakeholders, including Key Opinion Leaders (KOLs), Payers, Healthcare Professionals (HCPs), and Patient Advisory Groups.

Incorporating direct feedback from regulatory bodies ensures the value story is aligned with the requirements for market access and reimbursement.

Conclusion: Accelerating Approvals and Ensuring Commercial Success

Bridging existing intelligence limitations is fundamental to ensuring clinical success, drug development, regulatory approvals & licensing deals.

By moving away from fragmented processes and toward the integration of insights, innovative biotechs and life science clusters can significantly improve their Probability of Success.

Leveraging industry-specific AI and validated evidence allows teams to defend their licensing valuation, navigate the 90% clinical failure rate, and ensure their innovations successfully reach the patients who need them most.